Cel Sci (CVM) Change in Account Payables (2010 - 2026)
Cel Sci (CVM) posted Change in Account Payables of -$101031.0 for Q1 2026, down 241.96% sequentially from $71171.0 in Q4 2025, and up 72.64% YoY from -$58520.2 in Q1 2025.
Cel Sci (CVM) Change in Account Payables (2010 - 2026) Analysis & Trends
Cel Sci has reported Change in Account Payables for 16 years, with the latest figure at -$101031.0 in Q1 2026.
- Quarterly Change in Account Payables rose 72.64% year-over-year to -$101031.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$576779.0 (down 206.7% YoY) and the FY2025 annual result came in at -$442710.0, up 3.88% from the prior year.
- Change in Account Payables slipped to -$101031.0 in Q1 2026 per CVM's latest filing, from $71171.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $785426.0 in Q3 2022 and troughed at -$765078.0 in Q4 2023.
- A 5-year average of $13102.4 and a median of -$36225.0 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables sank 563.64% in 2023, then jumped 940.77% in 2024.
- Over 5 years, Change in Account Payables stood at -$115285.0 in 2022, then tumbled by 563.64% to -$765078.0 in 2023, then surged by 161.89% to $473514.0 in 2024, then plunged by 84.97% to $71171.0 in 2025, then slumped by 241.96% to -$101031.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$101031.0, $71171.0, and -$445154.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | -11,458.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101,031.00 |
| Mar 31, 2026 | -101,031.00 |
| Dec 31, 2025 | 71,171.00 |
| Dec 31, 2025 | 71,171.00 |
| Sep 30, 2025 | -445,154.00 |
| Sep 30, 2025 | -445,154.00 |
| Jun 30, 2025 | -101,765.00 |
| Jun 30, 2025 | -101,765.00 |
| Mar 31, 2025 | -369,305.00 |
| Mar 31, 2025 | -369,305.00 |
| Dec 31, 2024 | 473,514.00 |
| Dec 31, 2024 | 473,514.00 |
| Sep 30, 2024 | 131,794.00 |
| Sep 30, 2024 | 131,794.00 |
| Jun 30, 2024 | 304,569.00 |
| Jun 30, 2024 | 304,569.00 |
| Mar 31, 2024 | -131,861.00 |
| Mar 31, 2024 | -131,861.00 |
| Dec 31, 2023 | -765,078.00 |
| Dec 31, 2023 | -765,078.00 |